The review identified "material weaknesses" in its internal control over financial reporting and resulted in revisions of its balance sheet as of Dec. 31, 2022, and its cash flow statements for 2021 and 2022. In its twice-delayed results announcement, Chemours forecast first-quarter net sales to be flat to down sequentially and capital expenditures of about $100 million. It also forecast a 10% sequential decline in net sales for the titanium technologies segment due to seasonally weak demand for titanium, along with a drop in sales in its advanced performance materials segment.
– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned cancer institutions – BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline on March 25 by AVEO Pharmaceuticals, the text in the second paragraph has been corrected to better reflect Dr. Braendle's clinical research experience. The corrected release follows: AVEO Oncology
Average weekly trading volume of approximately 511,698 shares
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|
Simbolo | Ultimo prezzo | Variazione | % variazione |
---|---|---|---|